Posts by: Alice Melão

News

Invasive pulmonary artery denervation is safe and can improve the outcome of patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure, compared with standard of ... Read more

February 4, 2019February 7, 2019

Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients

News, PAH News

Preclinical and early clinical data showing the safety and potential therapeutic activity of rodatristat ethyl support its progression into Phase 2 trials in patients with pulmonary arterial hypertension (PAH). ... Read more

February 1, 2019February 8, 2019

Neurological Problems Possible in Premature Babies with BPD-related PH, Study Finds

News, PH News

Pulmonary hypertension (PH) is associated with poorer neurodevelopmental outcome and impaired growth in the first two years of life for preterm infants with bronchopulmonary dysplasia, a study shows. The ... Read more

January 11, 2019January 14, 2019

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

CTEPH News, News, PAH News

Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), ... Read more

January 2, 2019January 15, 2019

Delayed Diagnosis, More Comorbidities Affect Elderly PH Patients’ Prognosis, Study Suggests

News, PH News

Older patients diagnosed with pulmonary hypertension (PH) present a specific clinical profile and have a worse prognosis, a study shows. Given this, a patient’s age should be taken into ... Read more

December 6, 2018December 7, 2018

CTEPH Software Receives FDA’s Breakthrough Device Designation

CTEPH News

The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to software being developed by Bayer and Merck — known as MSD outside the U.S. and Canada — to ... Read more

December 5, 2018December 6, 2018

Uptravi, PAH Treatment, Now Publicly Funded in 9 of 10 Canadian Provinces

News, PAH News

Uptravi (selexipag) is now available with public funding for pulmonary arterial hypertension (PAH) patients in Canada living in nine of the country’s 1o provinces, patient groups announced. The governments ... Read more

November 30, 2018December 4, 2018

PhaseBio Advances New Phase 2b Trial to Test PB1046 in Patients with PAH

News, PAH News

PhaseBio Pharmaceuticals started dosing its investigational compound PB1046 in patients with pulmonary arterial hypertension (PAH) in a Phase 2b clinical trial. The first patient to receive the therapy was ... Read more

November 14, 2018November 28, 2018

Range of Clinical Trials Testing INOpulse System for PAH, PH-linked Lung Diseases, Bellerophon Announces

News, PAH News, PH News

INOpulse is advancing in a number of clinical trials as a potential treatment of pulmonary hypertension (PH) associated with several lung diseases, Bellerophon Therapeutics reported in a recent announcement. ... Read more

Posts by: Alice Melão

Alice Melão

Pulmonary Artery Denervation Can Improve CpcPH Patients’ Outcome, Trial Shows

Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients

Neurological Problems Possible in Premature Babies with BPD-related PH, Study Finds

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

Top 10 Pulmonary Hypertension Stories of 2018

Delayed Diagnosis, More Comorbidities Affect Elderly PH Patients’ Prognosis, Study Suggests

CTEPH Software Receives FDA’s Breakthrough Device Designation

Uptravi, PAH Treatment, Now Publicly Funded in 9 of 10 Canadian Provinces

PhaseBio Advances New Phase 2b Trial to Test PB1046 in Patients with PAH

Range of Clinical Trials Testing INOpulse System for PAH, PH-linked Lung Diseases, Bellerophon Announces

Pin It on Pinterest